HBOT Conversations:
Laurie Anderson (Part 2)
Healing COVID with HBOT
Dr. Laurie is a Doctor of Pharmacy, and a graduate of the University of North Carolina – Chapel Hill (UNC-CH) School of Pharmacy and the Pharmacy Practice Residency Program at the University of California – San Francisco (UCSF). Dr. Laurie spent many years in clinical practice, first as a neurosurgery clinical pharmacist at UCSF Medical Center and then as a general medicine and critical care clinical pharmacist at Duke Medical Center. For the past 14 years Dr. Laurie has been working in industry, and is currently a safety scientist in early phase drug development, designing safety strategies for First Time in Human clinical trials.
Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing. She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health. Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach. She discovered HBOT when she was struggling to heal from COVID, and now tells anyone who will listen about the power of oxygen and pressure.
Watch the Podcast
We continue Dr. Laurie Anderson’s HBOT News Network interview, diving in deeper to Hyperbaric Oxygen Therapy to heal COVID, and we bring up her struggles with Lyme Disease. Her interview is being released as a three part series, with Part 1 being released last week.
This podcast starts with our host, Ed di Girolamo, explaining to the audience that he and Dr. Laurie had a brief conversation before the interview, and they discussed autoimmune diseases, or the mechanisms of autoimmune diseases, that would include inflammation or hypoxia. He askes Dr. Laurie if this was discussed in her schooling when she got her doctorate in pharmacology. She explained that it was certainly talked about, but she really started to understand the trajectory of an underlying inflammatory process when she got sick. To help her heal, she applied her own medical knowledge to her healing process, and explains —
“But that wasn’t a cornerstone of what we learned, and it really became a cornerstone of my own healing, that getting control of inflammation was the way that my immune system was going to ramp back up and that my body was going to heal, unequivocally. It was all about addressing that inflammation.”
di Girolamo explains that years ago he attended a medical conference in Albuquerque that was specific to hyperbaric oxygen therapy, and he was on the edge of his seat for all three days. It was then that he started to truly understand how to read the science of HBOT. He brings up Lyme disease, which Dr. Laurie has personally struggled with, and recalls that there was a group of people there who have done HBOT and we’re so passionate in pushing it to help with Lyme disease because hyperbarics helped them, and they believe in it. di Girolamo states that through speaking to the medical profession about HBOT and Lyme, he has learned that Lyme disease is a virus and by doing a certain protocol of HBOT you’re essentially feeding the virus so much oxygen that it basically can not survive anymore and you “drown it”.
As the conversation progresses about Lyme disease, Dr. Laurie lists some symptoms and how HBOT helped her with tremendously with sleeping. After her first treatment she slept for 12 hours, which was unheard of for her. And she recalls that it was a very deep and refreshing sleep. She struggled for years and years with sleep from Lyme disease. Back then, HBOT was on the table as an alternative method of healing but she was only introduced to the mono-chambers and due to her extreme claustrophobia, it was not a healing avenue she wanted to explore at that time. She is thankful for the large multi-place chambers at Extivita that allowed Dr. Laurie to take a leap of faith and finally try HBOT.
Dr. Laurie’s career involves her reviewing the safety of clinical trials daily, so she explains that in order for a trial or study to be safe and effective, dosage is critical. di Girolamo explained that it’s the same for HBOT…. the right dosage of oxygen + pressure is critical to having healing success. He mentioned the podcasts with Dr. Stevens & Dr. Harch, as they both spoke in depth about dosage for hyperbaric oxygen therapy, especially for the indications that are considered to be “off label” for treatment with HBOT. Every person is unique and what works for one might not work the same for the next, so dosage can be tricky. But, in the end di Girolamo explains —
“I think at least in my conclusion, my humble opinion, is that any hyperbaric oxygen is better than no hyperbaric oxygen.”
Dr. Laurie referred to HBOT as a gift, because all that oxygen does so much for your brain. Which is exactly where it’s been proven to help veterans heal from PTSD, depression, anxiety, and even TBIs. She stresses that the mind-body connection is so strong, but it’s not talked about like it should be. In her opinion, she thinks that all that oxygen is strengthening the mind-body connection to the point where the brain is receiving that surge of oxygen and basically then signal the body that it’s ok…. let’s heal.
Stay tuned next week for Part 3 of Dr. Laurie’s podcast.
Guests
Dr. Laurie Anderson, Pharm.D.
Through her own journey navigating chronic illness, Dr. Laurie has explored and embraced many forms of alternative and non-traditional medicine to support her body for healing. She has gravitated towards practitioners and modalities that treat the whole patient, with the mantra that tending to mind, body and spirit is the true key to lasting health. Over the years, Dr. Laurie has discovered that this often leads to a ‘less is more’ approach.
When not working, Dr. Laurie is an avid gardener, ballroom dancer and traveler with her husband. Remaining curious and finding joy in every day are her super powers.
Subscribe Now, It’s Free!
Recent HBOT News
Healing under pressure: Inside a military hyperbaric chamber
At 16, she had a stroke. At 17, her town burned in the Camp Fire. Now, as her community rebuilds, she's healing thanks to hyperbaric therapy. SACRAMENTO, Calif — February 2, 2017, started off as an ordinary day for the Pipkin Family. Patrick and Stacey Pipkin just...
Clinical Trial – High-flow Oxygen for Vaso-occlusive Pain Crisis
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC),
which may evolve to acute chest syndrome (ACS), the most common cause of death among adult
patients with SCD. Currently, there is no safe and effective treatment to abort VOC or
prevent secondary ACS. Management of VOC mostly involve a symptomatic approach including
hydration, analgesics, transfusion, and incentive spirometry, which was investigated in a
very limited number of patients (<30).
The polymerisation of HbS is one major feature in the pathogenesis of vaso-occlusion. Among
factors determining the rate and extent of HbS polymer formation, the hypoxic stimulus is one
of the most potent and readily alterable. Current guidelines recommend oxygen therapy in
patients with VOC in order to maintain a target oxygen saturation of 95%. Low-flow nasal
oxygen (LFNO) is routinely used to achieve this normoxia approach, particularly in patients
at risk of secondary ACS because they may experience acute desaturation. In contrast, various
case series suggest a potential beneficial role of intensified oxygen therapy targeting
hyperoxia for the management of VOC, particularly with the use of hyperbaric oxygen, but the
latter is difficult to implement in routine clinical practice.
A recent high-flow nasal oxygen (HFNO) technology allows the delivery of humidified gas at
high fraction of inspired oxygen (FiO2) through nasal cannula. The FiO2 can be adjusted up to
100% (allowing hyperoxia that may reverse sickling) and the flow can be increased up to 60
L/min (which generates positive airway pressure and dead space flushing, that may prevent
evolution of VOC towards ACS by alleviating atelectasis and opioid-induced hypercapnia). In
patients with acute respiratory failure, HFNO has been shown to improve patient's comfort,
oxygenation, and survival as compared to standard oxygen or non-invasive ventilation.
The aim of the present study is to test the efficacy and safety of HFNO for the management of
VOC and prevention of secondary ACS. The investigators will use a multi-arm multi-stage
(MAMS) design to achieve these goals. HFNO will be delivered through AIRVO 2 (Fisher and
Paykel Healthcare, New Zealand), a device that incorporates a turbine allowing its use in
hospital wards.
Clinical Trial – Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
Subjects with Acute Myeloblastic Leukemia (AML) and myelodysplastic syndrome (MDS) who are
considered eligible for allogeneic stem cell transplant by the transplant team at WCI (Wilmot
Cancer Institute)will be enrolled in the study. Patients will receive Melphalan on day -2 and
HBO (Hyperbaric Oxygen) therapy on day 0 of the transplant. After neutrophil recovery is
documented, the patients will be seen in clinic at least weekly through day +100.